Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in pateints with essential hypertension
- PMID: 798576
- DOI: 10.1111/j.1445-5994.1976.tb03334.x
Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in pateints with essential hypertension
Abstract
Plasma renin activity (PRA), supine, erect and post-frusemide (1 mg/kg IV) was studied in 51 patients with previously untreated essential hypertension and their age- and sex-matched normotensive controls. Supine PRA, and the rise in PRA in response to the erect posture and frusemide, were significantly less in hypertensives compared to controls. When the hypertensives were arbitrarily divided into lower, mid, and upper subgroups according to supine PRA, the renin responsiveness was similar in each subgroup but significantly less in hypertensives compared to controls, subdivided in the same way. This does not support the existence of a separate "low renin" subgroup. The low supine PRA and reduced response to stimulation appears to be a feature of patients with essential hypertension. Thirty-nine of these hypertensives entered a double-blind cross-over drug trial of oxprenolol, methyldopa and spironolactone. All three drugs were equally effective in lowering the systolic and diastolic blood pressures in all three renin subgroups. Spironolactone caused a greater fall in systolic pressure in the lower renin group than in the other groups. Oxprenolol was the best tolerated drug, with only 5% of patients withdrawing due to side-effects compared to 13% on spironolacone and 29% on methyldopa.
Similar articles
-
Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in patients with essential hypertension.Aust N Z J Med. 1976 Aug;6(3 Suppl):60-1. Aust N Z J Med. 1976. PMID: 1071406 No abstract available.
-
Renin levels and spironolactone treatment in general practice: similar blood pressure lowering effect of spironolactone in low and normal renin patients.Eur J Clin Invest. 1977 Oct;7(5):389-92. doi: 10.1111/j.1365-2362.1977.tb01624.x. Eur J Clin Invest. 1977. PMID: 411668 Clinical Trial.
-
The effect of spironolactone (Aldactone) and methyldopa in low and normal renin hypertension.Acta Med Scand. 1975 Jun;197(6):451-6. doi: 10.1111/j.0954-6820.1975.tb04950.x. Acta Med Scand. 1975. PMID: 1098396 Clinical Trial.
-
Comparison of oxprenolol and methyldopa in hypertension. A within-patient double-blind trial.Lancet. 1976 Mar 6;1(7958):503-5. doi: 10.1016/s0140-6736(76)90293-2. Lancet. 1976. PMID: 55780 Clinical Trial.
-
A comparison between spironolactone and hydrochlorothiazide with and without alpha-methyldopa in the treatment of hypertension.Med J Aust. 1978 May 6;1(9):509-12. doi: 10.5694/j.1326-5377.1978.tb112590.x. Med J Aust. 1978. PMID: 353458 Clinical Trial.
Cited by
-
Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis.J Hum Hypertens. 2024 May;38(5):383-392. doi: 10.1038/s41371-023-00891-1. Epub 2024 Jan 11. J Hum Hypertens. 2024. PMID: 38200100 Free PMC article.
-
Treating hypertension. The place of beta blockade.Br Heart J. 1977 Aug;39(8):821-4. doi: 10.1136/hrt.39.8.821. Br Heart J. 1977. PMID: 20118 Free PMC article. Review. No abstract available.
-
ACE Inhibition to Distinguish Low-Renin Hypertension From Primary Aldosteronism.Hypertension. 2025 Jun;82(6):1046-1055. doi: 10.1161/HYPERTENSIONAHA.125.24711. Epub 2025 Mar 31. Hypertension. 2025. PMID: 40160086
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials